Padova

• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting
  2025-521797-34-00 5 2026-01-20 Diabetes Mellitus, Type 1
• STOP-HAE: A Phase 3 Study of ADX-324 in HAE Recruiting
  2025-521352-38-00 5 2026-01-16 Hereditary Angioedema
• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have not Responded to or … Recruiting
  2025-521034-28-00 4 2025-12-05 Moderate to Severe Rheumatoid Arthritis (RA)
• Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t … Recruiting
  2024-519479-24-00 4 2025-11-21 metastatic colorectal cancer
• A multicenter, prospective, randomized, double blind, placebo controlled, adaptive design study performed to evaluate the efficacy and the s … Recruiting
  2024-519623-23-00 5 2025-10-20 Venous leg ulcer
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting
  2025-520624-25-00 10 2025-09-19 Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
• Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S … Recruiting
  2022-501867-42-01 9 2025-09-08 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A randomized, placebo-controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with … Recruiting
  2024-516616-24-00 5 2025-07-23 Acromegaly
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE … Recruiting
  2024-512360-55-00 4 2025-06-30 Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
• Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD Recruiting
  2023-509370-39-00 5 2025-06-03 connective tissue diseases
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK10 … Recruiting
  2024-512659-19-00 10 2025-03-31 Advanced Melanoma

Showing 97–120 of 769 trials